HLB Group Appoints Eunyeong Yang as President and Head of Global Business Development
Former CHA Bio Group CBO Joins HLB Group
Commercialization System Strengthened Ahead of FDA Approval for Rivoceranib and More
HLB Group has appointed Eunyeong Yang, former Chief Business Officer (CBO) at CHA Bio Group, as President and Head of Bio Business Development.
According to HLB Group, this appointment is part of a strategic shift from an R&D-focused approach to a commercialization-centric strategy. As President, Yang will oversee global technology licensing and acquisition, joint development, strategic alliances for major pipelines within HLB Group, as well as the establishment of global partnerships and the overall commercialization strategy at the commercial stage.
Yang graduated from the College of Pharmacy at Seoul National University. She holds pharmacist licenses in Korea and the U.S. states of Colorado, Florida, and Michigan. She previously managed product strategy and marketing at Roche Korea and Eli Lilly Korea, and also worked as a pharmacist at hospitals and pharmacies in the United States. After serving as Global Sales Head at Samsung Biologics, she took on the role of CBO and Vice President at CHA Bio Group from 2022, leading business development for CHA Biotech, CHA Vaccine Institute, and CMG Pharmaceutical.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Moon Jeonghwan, Vice Chairman of Strategic Planning at HLB Group, stated, "With regulatory approvals for major pipelines such as the rivoceranib–camrelizumab combination therapy expected in July and lirafugratinib in September, HLB Group is at a critical juncture where we must translate R&D achievements into tangible business outcomes. President Yang is an expert in business development and global sales in the pharmaceutical and biotech industries both domestically and internationally, and we expect her to play a key role in advancing our commercialization strategy and expanding global collaboration opportunities."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
